what is the difference
IGF-1 LR3 and mecasermin
Two versions of one growth factor: the natural sequence, which is an approved medicine with a documented harm rate, and an engineered variant built to slip past the proteins that hold the natural one in check.
Insulin-like growth factor 1, usually written IGF-1, is the signal the liver releases when growth hormone reaches it, and it is what tells muscle and bone cells to grow. Mecasermin is that molecule made by recombinant means, and it is an approved medicine marketed as Increlex for children with severe primary IGF-1 deficiency. Its label describes a single chain of 70 amino acids with a sequence identical to the body's own IGF-1 [4]. In circulation, most native IGF-1 is held by carrier proteins that keep it inactive until it is needed.
IGF-1 LR3 is the same molecule rebuilt to evade those carriers. It runs to 83 amino acids: an arginine substituted at position 3 and a 13 amino acid extension added to the front, which together stop the IGF-binding proteins from holding it. The result stays free in circulation far longer and is described in the literature as considerably more potent than the native form. That modification is the selling point, and it is also the reason the native molecule's record does not carry across.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
The short answer
Mecasermin is native human IGF-1 and an approved drug, with 37 registrations naming it as an intervention on 2 August 2026 [7]. IGF-1 LR3 is a modified version of the same growth factor, and a registry search for it under either of its names returns nothing at all [7]. The published work on the modified form is in pigs, guinea pigs and cattle [1] [2] [3]. The approved native molecule's own labelling records hypoglycaemia, meaning blood sugar falling too low, in 30 of 71 subjects across five clinical studies, with four experiencing hypoglycaemic seizures or loss of consciousness [4].
Side by side
| Property | IGF-1 LR3 | Mecasermin |
|---|---|---|
| What it is | An 83 amino acid modified version of human IGF-1: arginine substituted at position 3, plus a 13 amino acid extension on the front end | Recombinant human IGF-1, the native 70 amino acid sequence, marketed as Increlex [4] |
| What the modification does | Prevents the IGF-binding proteins from holding the molecule, so it stays free in circulation far longer and is described in the literature as considerably more potent | None. The native molecule is bound and released by those carrier proteins in the ordinary way |
| Approval status | Not an approved drug in any country | FDA-approved for severe primary IGF-1 deficiency. The current labelling on DailyMed was published 20 May 2026 [4] |
| Registered human trials | 0. Searches for IGF-1 LR3 and for Long R3 IGF-1 return no studies [7] | 37 records name it as an intervention [7] |
| Where the published work sits | Farm and laboratory animals: infusion studies in finisher pigs [1], female guinea pigs [2] and beef heifers on restricted feed [3]. No human study of any design | Children with severe primary IGF-1 deficiency, in the trials behind the label and in a European registry of 242 children and adolescents across ten countries [4] [6] |
| What the animal work found | Not the picture the marketing describes. In finisher pigs a four-day infusion lowered average daily weight gain and feed intake and reduced circulating growth hormone, IGF-binding protein 3, IGF-1 and insulin [1] | Not applicable. The native molecule's record is human |
| Documented harm in the approved product's labelling | Nothing recorded, because nothing has been given to anyone in a study | Hypoglycaemia reported by 30 of 71 subjects, 42 percent, at least once. Five had severe episodes requiring assistance, and four had hypoglycaemic seizures or loss of consciousness [4] |
| Why that record does not transfer | The modified form is longer acting and not held by the binding proteins, so the exposure behind the native molecule's numbers is not this molecule's exposure | The label describes the native molecule at the exposures its trials produced, in the population those trials enrolled |
| Evidence grade on this site | Not graded. A grade is derived from tiered claim rows, and that source review has not been run here | Not graded here either. The label and the registry study are cited directly instead |
| What is missing | Any measurement in a person, on any route, including what a longer-acting form does to blood sugar | Any study of the modified form, which its own record cannot supply |
Why the two get mixed up
The name does most of the work. IGF-1 LR3 carries the name of the natural growth factor with a suffix attached, so it reads as a formulation of IGF-1 rather than as a different molecule, in the way that a modified-release tablet is still the same drug. It is not that kind of change. Thirteen extra amino acids and a substitution at position 3 alter how long the molecule stays active in circulation, which is the property the whole pharmacology turns on.
The second driver is that the native molecule has a genuine clinical file and it is easy to reach: an FDA-approved label, an adverse-reaction table with real numbers in it, and a paediatric endocrinology literature behind it [4] [6]. Any of that can be quoted next to the modified form without leaving the search results, and it will be accurate about a molecule nobody is selling. The direction of the borrowing is what makes this pair unusual. Most parent-molecule confusion imports a favourable trial result; here the native molecule's most quantified finding is a harm rate, which the modified form does not inherit either, and which nothing has measured for a version that lasts longer in circulation.
What the published record covers for each
The published work on the modified molecule is in farm and laboratory animals, and it points in a direction the marketing does not. In finisher pigs given a four-day infusion of Long R3 IGF-1, average daily weight gain and feed intake fell, and circulating growth hormone, IGF-binding protein 3, IGF-1 and insulin all decreased [Animal] [1]. In female guinea pigs infused for seven days, the fractional weights of the adrenals, gut, kidneys and spleen rose while overall growth did not, and circulating IGF-1, IGF-2 and binding proteins fell [Animal] [2]. In beef heifers losing weight on restricted feed, an eight-hour infusion tended to conserve whole-body and muscle protein while sharply lowering circulating amino acids and glucose [Animal] [3]. What this evidence can and cannot show: these results come from pigs, guinea pigs and cattle under controlled feeding, and the exposure is scaled to body weight in a way that does not translate directly. Mechanism in an animal does not establish an effect in a person.
The native molecule's record is human, and the most specific thing in it is a harm rate rather than a growth figure. Across five clinical studies covering 71 subjects with severe primary IGF-1 deficiency, followed for a mean of 3.9 years and 274 subject-years, the approved labelling records hypoglycaemia reported by 30 subjects, 42 percent, at least once. Five had severe episodes requiring assistance and treatment, and four had hypoglycaemic seizures or loss of consciousness on one or more occasions. Episodes were most frequent in the first month and in younger children [Human open-label] [4]. A European observational registry of 242 children and adolescents on the drug across ten countries, enrolled between 2008 and 2017, recorded treatment-emergent adverse events in 65.3 percent of patients, with hypoglycaemia the most common [Human open-label] [6].
One further piece of the record is about the body's own IGF-1 rather than about anything anyone took. In a prospective analysis of UK Biobank participants, higher circulating IGF-1 concentration was associated with higher incidence of colorectal, breast, prostate and thyroid cancer and lower incidence of ovarian and liver cancer, with the authors noting that reverse causality cannot be excluded [Human open-label] [5]. That is an observational association in people who were not given anything, and it is included because circulating IGF-1 concentration is what both molecules act on.
A 2026 review of performance compounds acting on the growth hormone and IGF-1 axis sets what clinicians report seeing in people who self-administer them against the peer-reviewed pharmacology [8]. The asymmetry between these two names is the whole page. One is an approved medicine whose labelling quantifies a specific harm in the population it was tested in. The other has never been given to a person under a protocol anyone wrote down.
Our takeThe approved native molecule carries a quantified harm rate in the population it was tested in. The modified version, which lasts longer and is not held by the binding proteins, has never been measured in a person at all.
Frequently asked questions
Is IGF-1 LR3 just a longer-lasting IGF-1?
It is a different molecule built from the same starting sequence. Native IGF-1 is 70 amino acids; the modified form runs to 83, with an arginine substituted at position 3 and a 13 amino acid extension on the front. Those changes stop the IGF-binding proteins from holding it, so it stays free in circulation far longer. That is a change in what the molecule does in a body, not a change in packaging.
How many human trials has IGF-1 LR3 been in?
None. A ClinicalTrials.gov search on 2 August 2026 for IGF-1 LR3 and for Long R3 IGF-1 returned no studies at all [7], and no published human study of the modified form is indexed. The published work is in finisher pigs, female guinea pigs and beef heifers [1] [2] [3].
What is mecasermin?
Recombinant human IGF-1, the native sequence, marketed as Increlex and approved for children with severe primary IGF-1 deficiency. Its current labelling on DailyMed was published 20 May 2026 [4]. It is a prescription medicine with an adverse-reaction table, a registry behind it [6], and a defined population it was studied in.
Does mecasermin's safety record apply to the modified form?
This site says no, and the reason is specific rather than procedural. The label's figures describe the native molecule at the exposures its trials produced, in the population those trials enrolled: 71 subjects with severe primary IGF-1 deficiency, followed for a mean of 3.9 years, with hypoglycaemia reported by 30 of them and hypoglycaemic seizures or loss of consciousness in four [4]. A version engineered to stay free in circulation longer produces a different exposure, and nothing has measured what that does to blood sugar in a person.
Why does the UK Biobank finding appear on this page?
Because it is about the exposure both molecules act on. In a prospective analysis of UK Biobank participants, higher circulating IGF-1 was associated with higher incidence of colorectal, breast, prostate and thyroid cancer and lower incidence of ovarian and liver cancer, and the authors noted that reverse causality cannot be excluded [5]. It was measured in people who were given nothing, so it is a fact about circulating concentration rather than about either product.
References
- Dunaiski V, Dunshea FR, Walton PE, Goddard C. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol. 1997. PMID 9488001 DOI 10.1677/joe.0.1550559
- Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995. PMID 7561636 DOI 10.1677/joe.0.1460247
- Hill RA, Hunter RA, Lindsay DB, Owens PC. Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. Domest Anim Endocrinol. 1999. PMID 10370861 DOI 10.1016/s0739-7240(99)00015-6
- US National Library of Medicine, DailyMed. INCRELEX (mecasermin) injection. FDA-approved prescribing information, label version published 20 May 2026. Section 6.1 records that across five clinical studies of 71 subjects with severe primary IGF-1 deficiency, treated for a mean of 3.9 years and representing 274 subject-years, hypoglycaemia was reported by 30 subjects (42%) at least once, five had severe hypoglycaemia on one or more occasions, and four experienced hypoglycaemic seizures or loss of consciousness. DailyMed, set id d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce. 2026. Label record
- Knuppel A, Fensom GK, Watts EL, Gunter MJ, Murphy N, Papier K, Perez-Cornago A, Schmidt JA, Smith Byrne K, Travis RC, Key TJ. Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank. Cancer Res. 2020. PMID 32709735 DOI 10.1158/0008-5472.CAN-20-1281
- Bang P, Woelfle J, Perrot V, Sert C, Polak M. Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome. Eur J Endocrinol. 2021. PMID 33434161 DOI 10.1530/EJE-20-0325
- US National Library of Medicine, ClinicalTrials.gov. Registry searches run through API v2 on 2 August 2026. Mecasermin as an intervention returned 37 records. Searches for IGF-1 LR3 and for Long R3 IGF-1, as a term and as an intervention, returned no studies. ClinicalTrials.gov. 2026. Registry search
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026. PMID 42395176 DOI 10.3389/fendo.2026.1822475